HBOT Conversations:
Dr. Peter Canaday (Part 1)
Dr. Peter Canaday has published work in Applied Physiology, Respiratory Medicine, and Diagnostic Radiology. He has presented at National (USA) and International meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on National, State, and Local advisory committees, and given testimony at the State Legislative level in the USA.
Dr. Canaday’s experience with Hyperbaric Oxygen Therapy dates back to the 1980s when he studied HBOT under Dr. Eric Kindwall, “The Father of Hyperbaric Medicine”. Dr. Canaday also co-founded the Hyperbaric Medicine Department at St. Anthony Hospital in Lakewood, Colorado.
From 2007, Dr. Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at a Midlands region DHB and served as Head of Department before retiring in March 2021.
Watch the Podcast
HBOT News welcomes Dr. Peter Canaday. Dr. Canaday now lives primarily in New Zealand, but his history with medicine and Hyperbaric Oxygen Therapy dates back over 40 years to the United States.
In this HBOT News Network Conversations, Dr. Canaday spends the first several minutes providing listeners with his biography and medical background. He also dives into his experience with Hyperbaric Oxygen Therapy in the 1980s.
The subject of PTSD and recent Hyperbaric research arises, and Dr. Canaday expands on the topic by referencing two research articles from Dr. Paul G. Harch –
Dr. Canaday further explains, “There is a recruitment of the anti-inflammatory enzymes and a suppression of the pro-inflammatory enzymes that can be achieved through even these lower pressure units. And so we’re beginning to see now the potential mechanism for which Hyperbaric Therapy, whether with or without oxygen, may be effective.”
The remainder of this HBOT News Conversation is specific to the topic of COVID-19. di Girolamo starts the conversation discussing the struggles for long-hauler COVID patients and the growing number of vaccine injuries as a result of the COVID-19 vaccine. Dr. Canaday agrees that the scientific inquiry for COVID-19 and the available information for associated vaccines has been widely suppressed. He continues that even the data which represent conclusions from peer-reviewed literature has been simply ignored, or set aside without discussion.
In response, Dr. Canaday provides viewers with direct links on how they can learn more about some of the data and information he’s shared with the public regarding the COVID-19 vaccine roll-outs:
Dr Peter Canaday – Pfizer Vaccine Discussion At The Town Hall
Courageous Convos with Special Guest Peter Canaday
Voices of Freedom on Odysee : search Peter Canaday
Dr. Canaday’s HBOT News Conversations is a two part series. Part 2 will air on Friday, December 16, 2022.
This HBOT News Conversation was filmed on October 4, 2022
Guest
Dr. Peter Canaday
Following completion of medical school at the University of Massachusetts in 1976, Dr. Peter Canaday took up training as an Internal Medicine specialist at the University of Michigan, followed by sub-specialist training in Respiratory and Intensive Care at the University of North Carolina. He began his medical career in a busy trauma hospital in Denver, Colorado in 1981 and practiced for 12 years. During his time there, he managed many of the types of patients now seen with severe COVID-19, co-founded a sleep disorders laboratory and a hyperbaric medicine department. As well, he participated in a dozen committee assignments, and rose to Chairman of the Department of Internal Medicine. In 1993, Dr Canaday changed career and completed training as a Radiologist at the University of Wisconsin in 1997. During an 8-year period at Creighton University Medical School in Nebraska, he became tenured as an Assistant Professor of Radiology, and head of the section of Pulmonary Radiology. He also served on or chaired over a dozen hospital and medical school committees and was appointed Clinical Coordinator for the Radiology Department during his time there. Dr Canaday has also published work in applied physiology, respiratory medicine, and diagnostic radiology, has presented at national (USA) and international meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on national, state, and local level advisory committees and given testimony at the state legislative level in the USA. From 2007, Dr Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at the Taranaki District Health Board and served as Head of Department before retiring in March 2021.
Subscribe Now, It’s Free!
Recent HBOT News
HBO: a possible supplementary therapy for oral potentially malignant disorders.
Abstract: Oral potentially malignant disorders (OPMDs) are chronic inflammatory diseases in which cells suffer hypoxia referring to deprivation of adequate oxygen supply. Hyperbaric oxygen treatment (HBO), which can increase oxygen tension and delivery to...
Clinical Trial – Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
During ascent to high altitude there is a physiologic response to hypoxia that results in an
elevated pulmonary arterial pressure associated with decreased exercise performance,
altitude-induced pulmonary hypertension, and high altitude pulmonary edema (HAPE). Riociguat
is a novel agent from Bayer Pharmaceuticals that has already demonstrated effectiveness in
the treatment of pulmonary hypertension, and it may prove to be beneficial in cases of
altitude-induced pulmonary hypertension or HAPE. This research study, composed of 20 healthy
volunteers ages 18-40 years, will attempt to mimic the decreased oxygen supply and elevated
pulmonary artery pressures found in conditions of high altitude, allowing observation of the
effects of riociguat and exercise on pulmonary arterial pressure, arterial oxygenation, and
exercise performance. Prior to entering the hypobaric chamber, subjects will have radial
arterial lines and pulmonary artery catheters placed to obtain arterial and pulmonary artery
pressure measurements. Subjects will then enter the hypobaric chamber and perform exercise
tolerance tests at a simulated altitude of 15,000 feet on an electrically braked ergometer
(exercise bike) before and after administration of riociguat. If, after administration of
riociguat and exposure to a simulated altitude of 15,000 feet, the exercise performance is
improved and observed pulmonary artery pressures are lower than those measurements seen prior
to administration of riociguat, this could lead to development of a prophylactic and/or
treatment strategy for HAPE and high-altitude pulmonary hypertension. Statistical analysis
will compare the variables of pulmonary artery pressure, radial arterial pressure,
ventilation rate, cardiac output, PaO2, and work rate at exhaustion before and after
administration of the drug riociguat. The investigator’s hypothesis is that riociguat will
decrease pulmonary artery pressure and improve gas exchange and exercise performance at
altitude.
Cervical spine osteomyelitis and epidural abscess after chemoradiotherapy for hypopharyngeal carcinoma: a case report.
Abstract: Osteomyelitis of mandible as a delayed adverse event following radiation therapy has been widely reported; however, osteomyelitis of the cervical spine has rarely been reported. In this study, we reported our experience with a case of cervical spine...